Axiom Investors LLC DE Invests $76.56 Million in Intuitive Surgical, Inc. $ISRG

Key Points

• Axiom Investors LLC DE has invested approximately $76.56 million in Intuitive Surgical by acquiring 154,580 shares.
• Intuitive Surgical has received positive forecasts from analysts, with a consensus rating of "Moderate Buy" and a target price of around $595.95.
• Insider activity includes significant sales, with Gary S. Guthart selling 29,360 shares, reducing his ownership by nearly 60%.

Axiom Investors LLC DE bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 154,580 shares of the medical equipment provider's stock, valued at approximately $76,559,000.

Other large investors have also recently bought and sold shares of the company. Castleark Management LLC raised its position in Intuitive Surgical by 3.4% in the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after purchasing an additional 2,990 shares during the last quarter. Arlington Trust Co LLC lifted its holdings in Intuitive Surgical by 34.5% during the first quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock worth $369,000 after acquiring an additional 191 shares during the period. Aveo Capital Partners LLC lifted its holdings in Intuitive Surgical by 37.4% during the first quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider's stock worth $390,000 after acquiring an additional 198 shares during the period. Aaron Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 3.2% during the first quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock worth $1,243,000 after acquiring an additional 78 shares during the period. Finally, Longbow Finance SA raised its stake in shares of Intuitive Surgical by 132.0% in the first quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider's stock valued at $9,756,000 after buying an additional 11,209 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Piper Sandler restated an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Evercore ISI lifted their price target on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Zacks Research cut Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. BTIG Research lifted their price target on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $8.93 during midday trading on Thursday, hitting $458.91. 987,569 shares of the company's stock were exchanged, compared to its average volume of 2,017,093. The stock has a 50-day moving average price of $489.31 and a two-hundred day moving average price of $510.50. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The company has a market cap of $164.51 billion, a P/E ratio of 63.85, a PEG ratio of 4.90 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the prior year, the business earned $1.78 EPS. The company's revenue for the quarter was up 21.4% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity

In other news, Director Amy L. Ladd sold 335 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the completion of the sale, the director owned 739 shares of the company's stock, valued at approximately $325,669.91. The trade was a 31.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gary S. Guthart sold 29,360 shares of the business's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares of the company's stock, valued at approximately $9,368,059.23. This trade represents a 59.69% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,224 shares of company stock valued at $21,716,492. Insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.